TSRO:NAS (USA) Also trade in: Germany

Tesaro Inc

$ 74.96 0 (0%)
Volume: 0 Avg Vol (1m): 0
Market Cap $: 4.13 Bil Enterprise Value $: 4.29 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -1276.51
Net Current Asset Value -3.52
Tangible Book -3.04
Projected FCF -50.05
Median P/S Value 464.52
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 3/10

Current vs industry vs history
Cash-to-Debt 0.74
Equity-to-Asset -0.18
Debt-to-Equity -4.92
Debt-to-EBITDA -1.11
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.52
DISTRESS
GREY
SAFE
Beneish M-Score -3.60
Not Manipulator
Manipulator

Profitability & Growth : 3/10

Current vs industry vs history
Operating Margin % -283.27
Net Margin % -295.67
ROE % -521.54
ROA % -85.37
ROC (Joel Greenblatt) % -5840.55
3-Year Total EBITDA Growth Rate -40.10
3-Year EPS w/o NRI Growth Rate -24.20

» TSRO's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:TSRO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:LOXO SHSE:603233 NAS:LGND NAS:ARRY XKRX:086900 LSE:ABC LSE:BTG XKRX:084990 NAS:AAAP XTER:MOR HKSE:00570 SZSE:000990 NAS:CLVS SZSE:002603 SZSE:300347 XSWX:IDIA NAS:ACAD SHSE:600161 NAS:FGEN SZSE:300009
Traded in other countries T8S.Germany
Address
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Ratios

Current vs industry vs history
PS Ratio 18.70
EV-to-EBIT -7.30
EV-to-EBITDA -7.42
EV-to-Revenue 19.58
Current Ratio 3.40
Quick Ratio 2.83
Days Inventory 375.59
Days Sales Outstanding 52.18
Days Payable 139.48

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -14.70

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.16
Earnings Yield (Joel Greenblatt) % -13.70

More Statistics

Revenue (TTM) (Mil) $ 219.37
EPS (TTM) $ -11.86
Beta 0
Volatility % 103.01
52-Week Range $ 23.41 - 75.16
Shares Outstanding (Mil) 55.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y